Some researches have shown surgery may acquire progression-free (PFS) benefit for selected patients with metastatic gastrointestinal stromal tumor (GIST) who received first-line imatinib and second-line sunitinib. However, impact of salvage surgery on pre-treated GIST patients receiving third-line regorafenib facing progression is not yet reported. Investigators retrospectively reviewed patients with regorafenib treatment with salvage surgery.
Between 2014 and 2019, 41 metastatic GIST patients received regorafenib therapy. 35 out of 41 metastatic GIST patients who were on regorafenib therapy facing progression and 15 experienced local progression underwent salvage surgery. Thirty-five of 41 (85.4 %) pre-treated GIST patients receiving regorafenib who experienced disease progression after a median follow-up of 12.4 months of regorafenib use. 15 out of 35 (42.9%) metastatic GIST patients receiving regorafenib facing progression underwent salvage surgery.
Study Type
OBSERVATIONAL
Enrollment
41
For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.
Chang Gung Memorial Hospital Linkou Branch
Taoyuan District, Taiwan
Overall survival
the time period from start regorafenib to death
Time frame: 01/2014~12/2019
Disease free survival
the time period after salvage surgery to disease reprogression
Time frame: 01/2014~12/2019
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.